MOL PHARM

MOLECULAR PHARMACOLOGY

A New Mechanism of 6-((2-(Dimethylamino)ethyl)amino)-3-hydroxy-7*H*-indeno(2,1-*c*)quinolin-7-one Dihydrochloride (TAS-103) Action Discovered by Target Screening with Drug-Immobilized Affinity Beads

Makoto Yoshida, Yasuaki Kabe, Tadashi Wada, Akira Asai, and Hiroshi Handa

Graduate School of Bioscience and Biotechnology, Tokyo Institute of Technology, Yokohama, Japan (M.Y.,Y.K.,T.W.,H.H.); Integrated Research Institute Graduate school of Bioscience and Biotechnology, Tokyo Institute of Technology, Yokohama, Japan (T.W.,H.H.); and Graduate School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan (A.A.)

ABSTRACT

6-((2-(Dimethylamino)ethyl)amino)-3-hydroxy-7*H*-indeno(2,1-*c*)-quinolin-7-one dihydrochloride (TAS-103) is a quinoline derivative that displays antitumor activity in murine and human tumor models. TAS-103 has been reported to be a potent topoisomerase II poison. However, other studies have indicated that cellular susceptibility to TAS-103 is not correlated with topoisomerase II expression. Because the direct target of TAS-103 remained unclear, we searched for a TAS-103 binding protein using high-performance affinity latex beads. We obtained a component of the signal recognition particle (SRP) as a TAS-103 binding protein. This component is a 54-kDa subunit (SRP54) of SRP, which mediates the proper delivery of secretory proteins in cells. We fractioned 293T cell lysates using gel-filtration chromatography and performed a coimmunoprecipitation assay using 293T cells expressing FLAG-tagged SRP54. The results revealed that TAS-103 disrupts SRP complex formation and reduces the amount of SRP14 and SRP19. TAS-103 treatment and RNAi-mediated knockdown of SRP54 or SRP14 promoted accumulation of the exogenously expressed chimeric protein interleukin-6-FLAG inside cells. In conclusion, we identified signal recognition particle as a target of TAS-103 by using affinity latex beads. This provides new insights into the mechanism underlying the effects of chemotherapies comprising TAS-103 and demonstrates the usefulness of the affinity beads.

Identifying proteins that bind specifically to drugs can help predict functions and estimate the efficacy of the drugs. It can also lead to novel drug development using computational designs based on information about drug binding proteins.

We reported previously the application of the high-performance affinity latex beads composed of a glycidyl-methacrylate-covered glycidylmethacrylate-styrene copolymer core for identifying drug receptors (Shimizu et al., 2000; Tomohiro et al., 2002). These latex beads have several advantages over conventional affinity purification of receptors. They enable the rapid and efficient purification of ligand- or drug-binding proteins (Ohtsu et al., 2005). These high-performance affinity beads have been used successfully for purification of various proteins, including transcription factors and drug receptors (Shimizu et al., 2000; Uga et al., 2006) and cisplatin-damaged DNA binding proteins (Tomohiro et al., 2002).

TAS-103 has been developed as an anticancer drug and displays antitumor activity in murine and human tumor models. It is a potent dual-inhibitor of topoisomerases (topo) I and II (Azuma and Urakawa, 1997; Utsugi et al., 1997), the enzymes associated with cleavage, passage, and recombination of DNA during DNA and RNA synthesis (Wang, 1985; Osheroff, 1989a) and exhibits powerful and broad antitumor activity against subcutaneously implanted human solid tumor xenografts, including cancers of the lung, pancreas, and kidney (Schabel et al., 1979; Kluza et al., 2000). Its topo I

aspet

ABBREVIATIONS: topo, topoisomerase; SRP, signal recognition particle; DMF, *N*,*N*-dimethylformamide; IL-6, interleukin-6; NE, nuclear extract; buffer E, Tris-HCl, NaCl, MgCl$_2$, CaCl$_2$, EDTA, and glycerol; NP-40, Nonidet P-40; PBS, phosphate-buffered saline; ER, endoplasmic reticulum; SN-38, 7-ethyl-10-hydroxycamptothecin; VP-16, 4′-demethylepipodophyllotoxin 9-(4,6-*O*-(*R*)-ethylidene-β-ᴅ-glucopyranoside).

inhibitory activity is similar to that of SN-38, and its topo II inhibitory activity is stronger than that of the inhibitor VP-16 (Utsugi et al., 1997; Sunami et al., 1999). TAS-103 does not show any cross-resistance in several resistant phenotypes such as *cis*-diamminedichloroplatinum(II) resistance, multidrug resistance, or topoisomerase inhibitor resistance (Sunami et al., 1999). It also enhances DNA cleavage in vitro in the presence of mammalian topo I and human topo IIα and IIβ. However, a study in yeast concluded that topo II is a primary cellular target of TAS-103 (Byl et al., 1999).

Although the levels of topo II expression have been shown to correlate with the sensitivity of cancer cells to topo II poisons (Takano et al., 1992), another study has shown that cellular susceptibility to TAS-103 is not correlated with topo II expression and is correlated with p300 expression (Torigoe et al., 2005). p300 functions together with Sp1 in GC-box-dependent transcription (Suzuki et al., 2000; Xiao et al., 2000). That study has also demonstrated that TAS-103 treatment enhances the interaction of Sp1 with p300 and induces SV40 promoter activity in a GC-box-dependent manner in cells in which p300 is highly expressed (Torigoe et al., 2005). Nevertheless, the direct target of TAS-103 has remained unclear. Therefore, we have searched for another target protein of TAS-103 using the high-performance affinity latex beads and have identified a component of the signal recognition particle (SRP) as a TAS-103 binding protein.

The SRP is a ribonucleoprotein complex composed of an Alu domain and an S domain in mammalian cells. The Alu domain contains two SRP proteins: SRP9 and SRP14. The S domain contains unique sequence SRP RNA and four SRP proteins: SRP19, SRP54, SRP68, and SRP72 (Politz et al., 2000). The SRP is bound through SRP54 to the signal peptides of membrane and secretory proteins emerging from the ribosome. After signal peptide recognition, the SRP is bound to membrane receptors to ensure the proper delivery of secretory proteins (Lutcke, 1995; Keenan et al., 2001; Zwieb and Eichler, 2002; Rosenblad et al., 2003). Low levels of SRP lead to insufficient targeting of proteins to the ER (Lakkaraju et al., 2007).

Here we show that TAS-103 is not only bound to SRP54 but also disrupts SRP complex formation and reduces the amount of the SRP14 subunit. We have used interleukin-6 (IL-6)-FLAG as a model secretory protein with a signal peptide. TAS-103 treatment increases the level of intracellular IL-6-FLAG protein, similar to RNAi-mediated knockdown of SRP54 or SRP14. We propose that TAS-103 disrupts SRP complex formation and causes degradation of SRP14 through its binding to SRP54. As a result, TAS-103 inhibits the function of the SRP in directing the delivery of secretory proteins.

Materials and Methods

TAS-103 Immobilization to Latex Beads. The TAS-103 derivative TAS-1-3383 (Fig. 1B) was fixed to latex beads (SGNGDENC beads) as described previously ((Shima et al., 2003) (Fig. 1C). The TAS-1-3383 was synthesized by Taiho Pharmaceutical Co., Ltd. (Tokyo, Japan) and was dissolved at 1 mM in *N*,*N*-dimethylformamide (DMF; Nacalai Tesque, Kyoto, Japan) containing 9 mM triethylamine, followed by diluting to 0.3 and 0.1 mM with DMF containing 9 mM triethylamine. The SGNGDENC beads (5 mg) were reacted with 0.2 mM *N*-hydroxysuccinimide and 0.2 mM *N*-ethyl-*N'*-(3-dimethylaminopropyl)-carbodiimide hydrochloride and then mixed with 500 μl of the 1.0, 0.3, and 0.1 TAS-1-3383 solutions for

16 h at room temperature. After removal of the supernatants to fresh tubes, 500 μl of 1 M ethanolamine, pH 8.5, was added to the beads and mixed for 2 h to block unreacted amino groups on the beads. The concentrations of residual *N*-hydroxysuccinimide in the supernatants were measured by high-performance liquid chromatography to quantify the immobilized TAS-1-3383.

Cell Cultures. HeLa spinner cells were grown in minimal essential medium containing 10% horse serum as described previously (Wada et al., 1991). HeLa and 293T cells were cultured in Dulbecco's modified Eagle's medium (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum, 50 U/ml penicillin, and 50 g/ml streptomycin. Cells were cultured at 37°C under an atmosphere of 5% CO_2.

Preparation of HeLa Cell Extracts. Nuclear extracts (NE) of HeLa cells were prepared as described previously (Dignam et al., 1983; Wada et al., 1998; Ohtsu et al., 2005). The extracts were dialyzed against buffer E (10 mM Tris-HCl, 50 mM NaCl, 1 mM $MgCl_2$, 1 mM $CaCl_2$, 0.2 mM EDTA, and 10% glycerol) without NP-40.

Affinity Purification of Drug-Binding Proteins. TAS-1-3383-fixed latex beads (0.3 mg) were equilibrated with buffer E, mixed with 200 μl of NE, incubated at 4°C for 4 h with occasional agitation, washed with buffer E three times, and then agitated in 50 μl of buffer E containing 10 mM TAS-103 at 4°C for 1 h to elute the binding protein(s). The protein was visualized by silver staining and Coomassie brilliant blue staining. Coomassie brilliant blue-

Fig. 1. Structures of the chemical compounds and preparation of TAS-1-3383-fixed latex beads. A, TAS-103. B, TAS-1-3383. C, preparation of TAS-103-immobilized affinity latex beads. TAS-1-3383, a newly synthesized derivative of TAS-103, was immobilized to SGNGDENC beads. The coupling reaction was performed as described under *Materials and Methods*.

stained bands were subjected to in-gel trypsin digestion, and the resultant peptides were analyzed by liquid chromatography/mass spectrometry.

RNase Treatment. Molecular biology-grade RNase A solution (5 μl) (U.S. Biochemical Corporation, Cleveland, OH) was added to the extracts before affinity purification.

Western Blotting. Total protein was quantified using a Bradford protein assay (Bio-Rad, Hercules, CA). Equal amounts of protein were loaded into SDS-polyacrylamide gels and transferred to poly-vinylidene difluoride filters (Millipore, Billerica, MA). Filters were blocked in blocking buffer (20 mM Tris-HCl, pH 7.6, 150 mM NaCl, 10% NaN$_3$, and 3% bovine serum albumin) and washed in Tris-buffered saline/Tween 20 (20 mM Tris-HCl, pH 7.6, 150 mM NaCl, and 0.1% Tween 20). The primary antibodies were anti-β-actin (Millipore Bioscience Research Agents, Temecula, CA), anti-SRP54 (BD Pharmingen, San Diego, CA), anti-SRP14 (Santa Cruz Biotechnology, Santa Cruz, CA), anti-FLAG (Sigma-Aldrich, St. Louis, MO), anti-SRP19, kindly provided by Dirk Görlich (Zentrum für Moleku-lare Biologie der Universität Heidelberg, Heidelberg, Germany) (Dean et al., 2001), and anti-SRP72-4 and anti-SRP68-2, kindly provided by Bernhard Dobberstein (Zentrum für Molekulare Biologie der Universität Heidelberg) (Lutcke et al., 1993; Bacher et al., 1999). The secondary antibodies conjugated to horseradish peroxidase were anti-mouse IgG (Sigma-Aldrich), anti-goat IgG (Santa Cruz Technology), and anti-rabbit IgG (Cell Signaling Technology, Danvers, MA). Signals were detected using the ECL system (GE Healthcare, Chalfont St. Giles, Buckinghamshire, UK) and Kodak BioMax films (Eastman Kodak, Rochester, NY).

Gel-Filtration Studies. The formation of the SRP was studied by gel-filtration chromatography using a SMART system and a Superose-6 PC 3.2/30 column (GE Healthcare). 293T cells were seeded into 60-mm collagen-coated dishes at 10×10^5 cells/dish. TAS-103 was added when the cultures had reached approximately 70 to 80% confluence. The cells were cultured for the next 12 h in the presence or absence of 10 μM TAS-103, collected with a scraper in PBS, washed with ice-cold PBS, lysed in 400 μl of 0.5% NP-40 lysis buffer (50 mM Tris-HCl, pH 8, 100 mM NaCl, and 0.5% NP-40) with occasional agitation, and centrifuged at 16,000g for 20 min at 4°C to remove any insoluble material. The supernatants were filtered with a 0.22-μm filter unit. The supernatants (50 μl) were loaded on the Superose-6 column equilibrated with the 0.5% NP-40 lysis buffer, and collected fractions were analyzed by Western blotting using antibodies against SRP54, SRP72, SRP68, and β-actin as a control. Molecular mass standards consisting of bovine serum albumin (66 kDa), alcohol dehydrogenase (150 kDa), horse spleen apoferritin (443 kDa), and bovine thyroglobulin (669 kDa) were used for calibration.

Construction of the FLAG-Tagged IL-6 Plasmid. A DNA insert encoding the FLAG-tagged human IL-6 fusion protein was constructed by polymerase chain reaction using the *IL-6* cDNA and the primers 5′-GATGATATCGAATTCATGAACTCCTTCTCCACAAGCG-3′ and 5′-GAGGATATCC TCGAGGACTCAGTCACTTAACTTGTCGT-CATCCTTGTAGTCCATCATTTGCCGAAGAGCCCTCAG-3′, followed by treatment with EcoRI and XhoI, and inserted into the expression vector pcDNA3.1 (Invitrogen) between the EcoRI and XhoI sites.

Construction of the FLAG-Tagged IL-6 Plasmid Lacking a Signal Peptide. A DNA insert encoding the FLAG-tagged human IL-6 fusion protein lacking a signal peptide was constructed by polymerase chain reaction using the *IL-6* cDNA and the primers 5′-GATGATATCGAATTCATGGCCCCAGTACCCCCAGGA-3′ and 5′-GAGGATATCCTCGAGGACTCAGTCACTTAACTTGTCGTCA-TCCTTGTAGTCCATCATTTGCCGAAGAGCCCTCAG-3′, followed by treatment with EcoRI and XhoI, and inserted into the expression vector pcDNA3.1 between the EcoRI and XhoI sites.

Immunoprecipitation. 293T cells were washed with ice-cold PBS, lysed in 250 μl of the 0.5% NP-40 lysis buffer with occasional agitation, and centrifuged at 16,000g for 10 min at 4°C to remove any insoluble material. ANTI-FLAG M2 Affinity Gel (Sigma) was equil-

ibrated in the 0.5% NP-40 lysis buffer. The supernatant (200 μl) was transferred to a fresh tube containing 20 μl of the equilibrated packed gel and incubated at 4°C with rotation for 3 h. The beads were collected by centrifugation at 500g for 5 min and washed three times with 1 ml of 0.5% NP-40 lysis buffer. The FLAG-tagged protein was competitively eluted with 50 μl of 0.5% NP-40 lysis buffer containing 0.2 μg/μl FLAG peptides.

Coimmunoprecipitation Assay. 293T cells were seeded into 60-mm collagen-coated dishes at 10×10^5 cells/dish. After 12 h, the cells were transfected with the plasmid pcDNA3-FLAG-HIS-SRP54. At 12 h after transfection, the medium was changed. TAS-103 was added when the cultures achieved approximately 70 to 80% confluence. The cells were cultured for the next 12 h in the presence or absence of 10 μM TAS-103, collected with a scraper in PBS, and washed with ice-cold PBS. The cells were lysed in 400 μl of 0.5% NP-40 lysis buffer with occasional agitation and centrifuged at 16,000g for 20 min at 4°C to remove any insoluble material. RNase A solution (5 μl) was added to the lysate before immunoprecipitation. The cell lysate (300 μl) was immunoprecipitated using ANTI-

Fig. 2. Affinity purification using TAS-1-3383-fixed beads. A, identification of the TAS-1-3383-binding protein. HeLa cell nuclear extracts were subjected to affinity purification using TAS-1-3383-fixed latex beads (lanes 2, 3, and 4) and the latex beads alone as a control (lane 1). The eluted proteins were subjected to silver staining. The asterisk indicates the specific band eluted from the TAS-1-3383-fixed latex beads. B, the eluted proteins (lanes 2, 3, 4, and 5) and nuclear extract (lane 1) were analyzed by Western blotting with anti-SRP54 antibody. C, the extracts treated with RNase A (lanes 1 and 2) and nontreated extracts (lanes 3 and 4) were subjected to affinity purification using the TAS-1-3383-fixed beads (lanes 2 and 4) and latex beads alone (lanes 1 and 3). The eluted fractions were analyzed by Western blotting with anti-SRP54 antibody.

FLAG-M2 agarose beads (Sigma). The eluted fraction and the whole-cell lysate were analyzed by Western blotting with anti-SRP54, anti-SRP68, anti-SRP72, anti-SRP19, anti-SRP14, and anti-β-actin.

Analysis of the Effects of RNAi-Mediated Knockdown of SRP54 or SRP14 on the Delivery of IL-6-FLAG. 293T cells were seeded into 60-mm collagen-coated dishes at 10×10^5 cells/dish. After 24 h, the cells were transfected with the plasmids pcDNA3.1-IL-6-FLAG or pcDNA3.1-IL-6ΔS-FLAG and the stealth RNAs (Invitrogen) using Lipofectamine 2000 (Invitrogen). The medium was changed 12 h later. After another 12 h, half of the cells were passaged in one plate and incubated for 24 h. The cells and culture media were collected at 48 h after transfection. The lysates were immunoprecipitated and analyzed by Western blotting. The sequences of the stealth RNAs were as follows: stealth RNA targeting SRP54: sense, 5′-GGATCCTGTCATCATTGCTTCTGAA-3′; and stealth RNA targeting SRP14: sense, 5′-GCTAACATGGATGGGCTGAAGAAG.A-3′.

Analysis of the Effects of TAS-103 on the Translocation of IL-6-FLAG. 293T cells were transfected with pcDNA3.1-IL-6-FLAG or pcDNA3.1-IL-6ΔS-FLAG, and the medium was changed after 16 h. The cells were cultured for another 8 h in the presence or absence of TAS-103. The cells and culture media were collected 24 h after transfection.

Results

The SRP Binds to TAS-103. TAS-103 is an anticancer drug that probably exerts its effect on tumor cell viability by inhibiting topoisomerase activity (Wang, 1985; Osheroff, 1989a; Azuma and Urakawa, 1997; Utsugi et al., 1997; Byl et al., 1999; Fortune et al., 1999; Ishida and Asao, 1999). However, other studies have indicated that cellular susceptibility to TAS-103 is not correlated with topo II expression (Torigoe et al., 2005). Because the direct target of TAS-103 remained unclear, we searched for other TAS-103 binding protein(s) in HeLa cell extracts using the high-performance affinity latex beads carrying a TAS-103 derivative, TAS-1-3383, which has an additional amino group for the coupling reaction with the carboxyl groups of the beads ((Shimizu et al., 2000; Ohtsu et al., 2005) (Fig. 1B).

We examined the biological activity of TAS-1-3383 before its immobilization on the beads. Cell viability assays were performed on HeLa cells cultured with TAS-103 or TAS-1-3383. The IC_{50} values were 40 and 500 nM for the cells cultured with TAS-103 and TAS-1-3383, respectively (data

Fig. 3. Effects of TAS-103 on the SRP complex. A, 293T cells alone and 293T cells treated with 10 μM TAS-103 for 12 h were lysed with 0.5% NP-40 lysis buffer. The lysates were subjected to Superose-6 gel filtration, and 18 fractions were collected. Each fraction was analyzed by Western blotting with antibodies for SRP54, SRP68, SRP72, and β-actin as a control. B, the intensities of SRP54 (left) and β-actin (right) in gel-filtration chromatography fractions were measured using NIH Image-J (http://rsb.info.nih.gov/ij/). The x-axis is the fraction number, and the y-axis is the intensity.

not shown). This result indicated that the additional amino group of TAS-1-3383 reduced its cytotoxicity on HeLa cells but that TAS-1-3383 still had a negative effect on tumor cell viability.

TAS-1-3383 was immobilized as shown in Fig. 1C. Three different concentrations of TAS-1-3383 in DMF were incubated with the latex beads, and the amounts of TAS-1-3383 immobilized on the surface of the beads were calculated as described under *Materials and Methods*. The concentrations of TAS-1-3383 were 1.1, 2.1, and 4.8 nmol/mg. Control beads without the TAS-103 derivative were also used. HeLa cell nuclear extracts were incubated with each of the beads for 12 h. The beads with bound proteins were washed three times, and then the proteins were recovered from the beads in the presence of 10 mM TAS-103. The proteins were subjected to SDS-polyacrylamide gel electrophoresis and visualized by silver staining. We observed several bands in all lanes; however, a single band with a molecular mass of 54 kDa was detected only in lanes containing material from the TAS-1-3383-immobilized beads (Fig. 2A). Furthermore, the band intensity increased with increasing concentrations of TAS-1-3383 on the beads (Fig. 2A). These results indicate that the 54-kDa band is specific for the immobilized TAS-1-3383.

We analyzed the 54-kDa protein by liquid chromatography/ mass spectrometry and found that it might be SRP54, a component of the SRP. To test whether the 54-kDa band was SRP54, we carried out Western blot analysis with anti-SRP54 antibody. The antibody reacted with the 54-kDa protein, and the band intensity increased in proportion to the amount of TAS-1- 3383 immobilized on the beads (Fig. 2B). These results indicate that SRP54 was specifically bound to TAS-1-3383 on beads and was eluted competitively by the addition of TAS-103.

TAS-103 Disrupts SRP Complex Formation. We investigated whether TAS-103 affects SRP complex formation. We chose 293T cells for this assay because 293T whole-cell lysates can be readily prepared under mild detergent conditions. The 293T were incubated for 12 h with or without 10 μM TAS-103 and lysed in lysis buffer containing 0.5% NP-40. The cell extracts were fractionated by gel-filtration chromatography as described under *Materials and Methods*. Each fraction was analyzed by Western blotting with anti-SRP54, anti-SRP68, anti-SRP72, and anti-β-actin antibodies (see *Materials and Methods* for experimental details). SRP68 and SRP72 were observed in fractions 7, 8, and 9 regardless of TAS-103 treatment. In contrast, SRP54 was observed primarily in fractions 8 to 11 of cells cultured without TAS-103, whereas it was observed in fractions 8 to 12, and abundantly in fractions 11 and 12, of cells cultured with TAS-103, indicating that the addition of TAS-103 caused SRP54 to distribute in later fractions (Fig. 3A). TAS-103 treatment did not affect the distribution of β-actin, which was detected in fractions 11 to 14. The band intensities of the SRP54 and β-actin proteins were measured using NIH Image-J software (http:// rsb.info.nih.gov/ij/) and plotted in Fig. 3B, which shows the clear difference in SRP54 distribution with TAS-103 treatment (Fig. 3B, left). In contrast, the control β-actin distribution was similar in fractions 10 to 14 regardless of the treatment (Fig. 3B, right). These results indicate that TAS-103 releases SRP54 from SRP68 and SRP72.

To better understand the effects of TAS-103 on the inter-

actions between SRP54 and other subunits, we performed a coimmunoprecipitation assay. We overexpressed FLAG-tagged SRP54 in 293T cells. Untreated 293T cells were used as a control. The 293T cells were incubated for 12 h with or without 10 μM TAS-103 and lysed in lysis buffer containing 0.5% NP-40. The overexpressed FLAG-tagged SRP54 was immunoprecipitated using ANTI-FLAG-M2 agarose beads and released from the beads using FLAG peptide. The eluates were analyzed by Western blotting with anti-SRP54, anti-SRP68, anti-SRP72, anti-SRP19, anti-SRP14, and anti-β-actin antibodies (Fig. 4A). These SRP subunits were detected in the eluates from the 293T cells overexpressing SRP54-FLAG (Fig. 4A, lanes 2 and 4), whereas no bands

Fig. 4. Effects of TAS-103 on the interactions between SRP54 and other subunits. A, pcDNA3.1-FLAG-HIS-SRP54 was transfected into 293T cells. The cells were incubated for 12 h with or without 10 μM TAS-103 and lysed in lysis buffer containing 0.5% NP-40. The lysates were treated with RNaseA (lanes 5, 6, 11, and 12). Overexpressed FLAG-tagged SRP54 was immunoprecipitated using ANTI-FLAG-M2 agarose beads and released from the beads using FLAG peptide. The eluted fractions were analyzed by Western blotting with anti-SRP54, anti-SRP68, anti-SRP72, anti-SRP19, anti-SRP14, and anti-β-actin antibodies (lanes 1 to 6). Whole-cell lysates were also analyzed with the antibodies (lanes 7 to 12). B, 293T cells were treated with or without 1, 3, or 10 μM TAS-103 for 12 h, and the lysates were analyzed by Western blotting.

were detected in the eluates from control cells (Fig. 4A, lanes 1 and 3). The band intensities of SRP68 and SRP72 were decreased in the eluates from cells grown with TAS-103 (Fig. 4A; compare lanes 2 and 4). These data indicate that SRP68 and SRP72 are released from SRP54 by the addition of TAS-103, consistent with the results of the gel-filtration assay shown in Fig. 3.

Furthermore, the band intensities of SRP14 and SRP19 were decreased in the whole-cell lysates from cells treated with TAS-103 (Fig. 4A; compare lanes 7 and 9 and lanes 8 and 10, respectively). The decreases were dose-dependent (Fig. 4B). However, SRP14 mRNA was unaffected by treatment with TAS-103 (data not shown). These results suggest that TAS-103 causes the disruption of the SRP complex, resulting in destabilization of SRP14 and SRP19 and its eventual degradation. Further in-depth studies are required to elucidate the mechanism in detail.

TAS-103 Treatment and the Knockdown of SRP54 and SRP14 Cause an Intracellular Increase in IL-6-FLAG. The SRP interacts with signal sequences that appear on the surface of translating ribosomes. After signal-peptide recognition, the SRP is bound to membrane receptors and ensures the proper delivery of secretory proteins (Lutcke, 1995; Keenan et al., 2001; Zwieb and Eichler, 2002; Rosenblad et al., 2003). We hypothesized that TAS-103 inhibits the translocation of proteins into the ER, thereby leading to the inhibition of translocation across the ER and resulting in the accumulation of secretory proteins in the cells.

IL-6 is a multifunctional cytokine that is produced by many cells after appropriate stimulation. IL-6 has a signal peptide for sorting and directing it to the ER via the SRP during translation. IL-6 lacking the signal peptide accumulates within the cytoplasm of transfected cells (Rose-John et al.,

1993). Therefore, to examine whether TAS-103 causes secretory proteins with signal peptides to accumulate in cells, we used IL-6-FLAG with its signal peptide as a model and IL-6ΔS-FLAG lacking the signal peptide (IL-6ΔS-FLAG) as a negative control.

293T cells were transfected with pcDNA3.1-IL-6-FLAG or pcDNA3.1-IL-6ΔS-FLAG and cultured for 16 h. After a medium change, the cells were incubated with or without TAS-103 for another 8 h. The cell lysates and culture media were immunoprecipitated by anti-FLAG antibody, followed by Western blot analysis. The results showed that TAS-103 caused an increase in IL-6-FLAG in the cell lysates (Fig. 5A), but had no effect on the accumulation of IL-6ΔS-FLAG (Fig. 5B).

To test whether specific reductions in SPR54 or SRP14 protein affected the accumulation of IL-6-FLAG or IL-6ΔS-FLAG in cells, we performed RNAi-mediated knockdowns of SRP54 and SRP14. The cells were cotransfected with the pcDNA3.1-IL-6-FLAG plasmid or -IL-6ΔS-FLAG plasmid and stealth RNA targeting SRP14 or SRP54 or control stealth RNA containing a scrambled sequence. The cell lysates and culture media were immunoprecipitated followed by Western blot analysis. The specific knockdowns of SRP54 and SRP14 were confirmed by Western blot analysis (Fig. 5C). The results showed that the reductions in SRP54 or SRP14 proteins increased intracellular IL-6-FLAG compared with the treatment with stealth RNA containing the scrambled sequence (Fig. 5C). In contrast, in cells cotransfected with the pcDNA3.1-IL-6ΔS-FLAG plasmid and the stealth RNAs, the reductions in SRP54 or SRP14 protein had no effect on the amount of intracellular IL-6ΔS-FLAG (Fig. 5D). Thus, treatment with TAS-103 and the specific knockdowns of SRP54 or SRP14 had similar effects on the accumulation of intracellular IL-6-FLAG. These results suggest that

Fig. 5. Effects of TAS-103 and knockdowns of SRP14 or SRP54 on the translocation of IL-6-FLAG. A, 293T cells were transfected with pcDNA3.1-IL-6-FLAG followed by a medium change after 16 h. The cells were cultured for another 8 h in the presence (lanes 3–5) or absence (lane 2) of TAS-103. The cells and culture media were collected 24 h after transfection. The lysates and culture media were immunoprecipitated and analyzed by Western blotting. B, 293T cells were transfected with pcDNA3.1-IL-6ΔS-FLAG followed by a medium change after 16 h. The cells were cultured for another 8 h in the presence (lanes 3–5) or absence (lane 2) of TAS-103. The cells and culture media were collected 24 h after transfection. The lysates and culture media were immunoprecipitated and analyzed by Western blotting. C, 293T cells were cotransfected with the plasmid pcDNA3.1-IL-6-FLAG and stealth RNAs containing a scrambled sequence (lane 2) or targeting SRP14 (lane 3) or SRP54 (lane 4). The cells and culture media were collected 48 h after transfection. The lysates and culture media were immunoprecipitated and analyzed by Western blotting. D, 293T cells were cotransfected with the plasmid pcDNA3.1-IL-6ΔS-FLAG and stealth RNAs containing a scrambled sequence (lane 2) or targeting SRP14 (lane 3) or SRP54 (lane 4). The cells and culture media were collected 48 h after transfection. The lysates and culture media were immunoprecipitated and analyzed by Western blotting.

TAS-103 treatment causes the accumulation of intracellular IL-6-FLAG by inhibiting the SRP and thereby disrupting proper protein delivery.

Discussion

We have identified SRP54 as a protein associated with TAS-103 using affinity latex beads. The addition of TAS-103 dissociates SRP54 from TAS-1-3383 immobilized to the latex beads. Although SRP54 has been reported to be localized in the cytosol (Politz et al., 2000), we observe abundant SRP54 in HeLa cell nuclear extracts (Fig. 2B). Because DNA also has been considered to be a major target of TAS-103 (Ishida and Asao, 1999), we predicted that TAS-103 bound to SRP54 via nucleic acid. However, SRP54 was bound to the drug in the lysates treated with RNaseA (Fig. 2C), and the coimmunoprecipitation assay using FLAG-tagged SRP54 showed that SRP14 was released by the RNaseA treatment (Fig. 4A). We therefore deduce that SRP54 is a TAS-103-binding protein.

TAS-103 is classified as a topo II poison (Byl et al., 1999). Nevertheless, we did not find any topo II associated with TAS-103 (data not shown). We investigated TAS-103 binding proteins from the NE lysate lacking abundant supercoiled DNA, whereas TAS-103 stabilizes the covalently linked topo II-DNA complex called the "cleavable complex" (Willmore et al., 1998). In the drug-stabilized cleavable complex, topo II molecules are covalently bound to a DNA strand end at the double-strand break, thereby preventing religation of the DNA strands (Osheroff, 1989b). These stabilized complexes are believed to make the break permanent and inhibit DNA replication, leading to mutations, recombination events, and chromosome aberrations (Chen et al., 1996). We obtained a TAS-103 binding protein from NE lysates that did not contain abundant supercoiled DNA, whereas TAS-103 probably recognizes topoisomerases bound to supercoiled double-stranded DNA in cells. This may be a reason why topoisomerases were not obtained from the beads in our study, although further in-depth studies will be required to address this question.

We have shown that TAS-103 disrupts SRP complex formation and decreases the amounts of SRP14 and SRP19 in cells. SRP14 mRNA was not affected by the addition of TAS-103. Therefore, these results suggest that TAS-103 destabilizes SRP14 and SRP19 through the disruption of the SRP complex.

The SRP interacts with signal sequences appearing on the surface of translating ribosomes followed by binding to membrane receptors to ensure the proper delivery of secretory proteins (Lutcke, 1995; Zwieb and Eichler, 2002; Rosenblad et al., 2003). We have used IL-6-FLAG as a model protein with a signal peptide that is delivered by the SRP and IL-6-FLAG lacking a signal peptide (IL-6ΔS-FLAG) as a negative control. We have examined the effects of TAS-103 and knockdowns of SRP54 and SRP14 on the translocation of IL-6-FLAG and IL-6ΔS-FLAG and found that they increase intracellular IL-6-FLAG, whereas they have no effect on the amount of IL-6ΔS-FLAG. Therefore, we hypothesize that the accumulation is caused by the disruption of post-translational translocation. We have observed that the addition of TAS-103 or RNAi-mediated knockdowns lead to increases in two types of intracellular IL-6-FLAG with different molecu-lar masses. The reason for this is unknown; however, the increase in the molecular weight of the intracellular IL-6-FLAG was the same with the TAS-103 treatment as with the knockdowns.

Although we observed the accumulation of IL-6-FLAG caused by RNAi-mediated knockdowns of SRP14 or SRP54 or TAS-103 treatment, no corresponding decrease of IL-6-FLAG in the culture media was detected. The amount of IL-6-FLAG secreted from 293T cells into the culture media was found to be 20- to 40-fold more than the amount inside the cells (data not shown). The amount of intracellular IL-6-FLAG in cells treated with TAS-103 was two to four times more than in untreated cells. We speculate that the difference in the amount of IL-6-FLAG secreted into the culture media by TAS-103-treated and untreated cells was very small and therefore undetectable by Western blot analysis.

From these observations, we propose that the interaction between SRP and TAS-103 results in the disruption of SRP complex formation and degradation of SRP14 and SRP19, eventually inhibiting SRP function. This provides new insights into the mechanism underlying the effects of chemotherapies comprising TAS-103.

Currently, various chemical genetic approaches for the probing of potential interactions between large numbers of chemical compounds and potential targets are being actively explored for drug discovery. This work describes the usefulness of our affinity beads for providing high-quality chemical genetic information.

References

Azuma R and Urakawa A (1997) Simultaneous determination of a novel anticancer drug, TAS-103, and its N-demethylated metabolite in monkey plasma by high-performance liquid chromatography using solid-phase extraction. *J Chromatogr B Biomed Sci Appl* **691:**179–185.
Bacher G, Pool M, and Dobberstein B (1999) The ribosome regulates the GTPase of the beta-subunit of the signal recognition particle receptor. *J Cell Biol* **146:**723–730.
Byl JA, Fortune JM, Burden DA, Nitiss JL, Utsugi T, Yamada Y, and Osheroff N (1999) DNA topoisomerases as targets for the anticancer drug TAS-103: primary cellular target and DNA cleavage enhancement. *Biochemistry* **38:**15573–15579.
Chen CL, Fuscoe JC, Liu Q, and Relling MV (1996) Etoposide causes illegitimate V(D)J recombination in human lymphoid leukemic cells. *Blood* **88:**2210–2218.
Dean KA, von Ahsen O, Gorlich D, and Fried HM (2001) Signal recognition particle protein 19 is imported into the nucleus by importin 8 (RanBP8) and transportin. *J Cell Sci* **114 (Pt 19):**3479–3485.
Dignam JD, Lebovitz RM, and Roeder RG (1983) Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. *Nucleic Acids Res* **11:**1475–1489.
Fortune JM, Velea L, Graves DE, Utsugi T, Yamada Y, and Osheroff N (1999) DNA topoisomerases as targets for the anticancer drug TAS-103: DNA interactions and topoisomerase catalytic inhibition. *Biochemistry* **38:**15580–15586.
Ishida K and Asao T (1999) Interaction of a novel antitumor agent TAS-103 with DNA. *Nucleic Acids Symp Ser* **42:**129–130.
Keenan RJ, Freymann DM, Stroud RM, and Walter P (2001) The signal recognition particle. *Annu Rev Biochem* **70:**755–775.
Kluza J, Lansiaux A, Wattez N, Mahieu C, Osheroff N, and Bailly C (2000) Apoptotic response of HL-60 human leukemia cells to the antitumor drug TAS-103. *Cancer Res* **60:**4077–4084.
Lakkaraju AK, Luyet PP, Parone P, Falguieres T, and Strub K (2007) Inefficient targeting to the endoplasmic reticulum by the signal recognition particle elicits selective defects in post-ER membrane trafficking. *Exp Cell Res* **313:**834–841.
Lutcke H (1995) Signal recognition particle (SRP), a ubiquitous initiator of protein translocation. *Eur J Biochem* **228:**531–550.
Lutcke H, Prehn S, Ashford AJ, Remus M, Frank R, and Dobberstein B (1993) Assembly of the 68- and 72-kD proteins of signal recognition particle with 7S RNA. *J Cell Biol* **121:**977–985.
Ohtsu Y, Ohba R, Imamura Y, Kobayashi M, Hatori H, Zenkoh T, Hatakeyama M,

Manabe T, Hino M, Yamaguchi Y, et al. (2005) Selective ligand purification using high-performance affinity beads. *Anal Biochem* **338:**245–252.

Osheroff N (1989a) Biochemical basis for the interactions of type I and type II topoisomerases with DNA. *Pharmacol Ther* **41:**223–241.

Osheroff N (1989b) Effect of antineoplastic agents on the DNA cleavage/religation reaction of eukaryotic topoisomerase II: inhibition of DNA religation by etoposide. *Biochemistry* **28:**6157–6160.

Politz JC, Yarovoi S, Kilroy SM, Gowda K, Zwieb C, and Pederson T (2000) Signal recognition particle components in the nucleolus. *Proc Natl Acad Sci U S A* **97:**55–60.

Rose-John S, Schooltink H, Schmitz-Van de Leur H, Mullberg J, Heinrich PC, and Graeve L (1993) Intracellular retention of interleukin-6 abrogates signaling. *J Biol Chem* **268:**22084–22091.

Rosenblad MA, Gorodkin J, Knudsen B, Zwieb C, and Samuelsson T (2003) SRPDB: Signal Recognition Particle Database. *Nucleic Acids Res* **31:**363–364.

Schabel FM Jr, Trader MW, Laster WR Jr, Corbett TH, and Griswold DP Jr (1979) cis-Dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice. *Cancer Treat Rep* **63:**1459–1473.

Shima D, Yugami M, Tatsuno M, Wada T, Yamaguchi Y, and Handa H (2003) Mechanism of H-8 inhibition of cyclin-dependent kinase 9: study using inhibitor-immobilized matrices. *Genes Cells* **8:**215–223.

Shimizu N, Sugimoto K, Tang J, Nishi T, Sato I, Hiramoto M, Aizawa S, Hatakeyama M, Ohba R, Hatori H, et al. (2000) High-performance affinity beads for identifying drug receptors. *Nat Biotechnol* **18:**877–881.

Sunami T, Nishio K, Kanzawa F, Fukuoka K, Kudoh S, Yoshikawa J, and Saijo N (1999) Combination effects of TAS-103, a novel dual topoisomerase I and II inhibitor, with other anticancer agents on human small cell lung cancer cells. *Cancer Chemother Pharmacol* **43:**394–401.

Suzuki T, Kimura A, Nagai R, and Horikoshi M (2000) Regulation of interaction of the acetyltransferase region of p300 and the DNA-binding domain of Sp1 on and through DNA binding. *Genes Cells* **5:**29–41.

Takano H, Kohno K, Matsuo K, Matsuda T, and Kuwano M (1992) DNA topoisomerase-targeting antitumor agents and drug resistance. *Anticancer Drugs* **3:**323–330.

Tomohiro T, Sawada Ji J, Sawa C, Nakura H, Yoshida S, Kodaka M, Hatakeyama M, Kawaguchi H, Handa H, and Okuno H (2002) Total analysis and purification of cellular proteins binding to cisplatin-damaged DNA using submicron beads. *Bioconjug Chem* **13:**163–166.

Torigoe T, Izumi H, Wakasugi T, Niina I, Igarashi T, Yoshida T, Shibuya I, Chijiiwa K, Matsuo K, Itoh H, et al. (2005) DNA topoisomerase II poison TAS-103 trans-activates GC-box-dependent transcription via acetylation of Sp1. *J Biol Chem* **280:**1179–1185.

Uga H, Kuramori C, Ohta A, Tsuboi Y, Tanaka H, Hatakeyama M, Yamaguchi Y, Takahashi T, Kizaki M, and Handa H (2006) A new mechanism of methotrexate action revealed by target screening with affinity beads. *Mol Pharmacol* **70:**1832–1839.

Utsugi T, Aoyagi K, Asao T, Okazaki S, Aoyagi Y, Sano M, Wierzba K, and Yamada Y (1997) Antitumor activity of a novel quinoline derivative, TAS-103, with inhibitory effects on topoisomerases I and II. *Jpn J Cancer Res* **88:**992–1002.

Wada T, Takagi T, Yamaguchi Y, Ferdous A, Imai T, Hirose S, Sugimoto S, Yano K, Hartzog GA, Winston F, et al. (1998) DSIF, a novel transcription elongation factor that regulates RNA polymerase II processivity, is composed of human Spt4 and Spt5 homologs. *Genes Dev* **12:**343–356.

Wada T, Watanabe H, Usuda Y, and Handa H (1991) Different biological activities of the hetero- and homodimers formed by the 47- and 43-kilodalton proteins of transcription factor ATF/E4TF3. *J Virol* **65:**557–564.

Wang JC (1985) DNA topoisomerases. *Annu Rev Biochem* **54:**665–697.

Willmore E, Frank AJ, Padget K, Tilby MJ, and Austin CA (1998) Etoposide targets topoisomerase IIα and IIβ in leukemic cells: isoform-specific cleavable complexes visualized and quantified in situ by a novel immunofluorescence technique. *Mol Pharmacol* **54:**78–85.

Xiao H, Hasegawa T, and Isobe K (2000) p300 collaborates with Sp1 and Sp3 in p21(waf1/cip1) promoter activation induced by histone deacetylase inhibitor. *J Biol Chem* **275:**1371–1376.

Zwieb C and Eichler J (2002) Getting on target: the archaeal signal recognition particle. *Archaea* **1:**27–34.

Address correspondence to: Dr. Hiroshi Handa, Graduate School of Bioscience and Biotechnology, Tokyo Institute of Technology, 4259 Nagatsuta-cho, Midori-ku, Yokohama, Kanagawa, 226-8501, Japan. E-mail: hhanda@bio.titech.ac.jp